Psychedelic Stocks Archives - Page 2 of 61

MondayFeb 24, 2025 10:00 am

Why Funding Isn’t All That Web3 Startups Need

In the world of startups, funding is often seen as the biggest hurdle that many have to jump. Many believe that once a company secures financial backing, success will follow. However, for Web3 startups, funding is just the beginning. Unlike traditional Web2 businesses, Web3 companies face unique challenges, including regulatory issues, security concerns, community building, and the need for strategic partnerships. Without these elements, even well-funded Web3 startups may struggle to succeed. Launching a Web3 startup requires more than just building a product; it demands a clear go-to-market (GTM) strategy for success. Traditional Web2 businesses rely on paid ads and…

MondayFeb 24, 2025 10:00 am

Washington State Bills Seek to Legalize Psychedelics for Therapeutic Use

A pair of bills filed in the Washington State legislature seeks to legalize psychedelics, particularly psilocin and psilocybin, for medicinal purposes in clinical settings. One bill was filed in the state senate while the other was filed in the assembly. Both bills seek to legalize these hallucinogens for adults aged 21 or older. Alex Ramel, a state Representative who co-sponsored the house bill (HB 1433), says he has tracked some research on the subject and it is clear that the combination of talk therapy and psychedelics administered in a medical setting can be a powerful way to treat individuals with…

WednesdayFeb 19, 2025 10:00 am

Veterans Turn to One Another for Help Using Psychedelics to Combat Mental Health Challenges

With the existing treatments for mental health issues like PTSD, treatment-resistant depression and suicidal thoughts having limited, if any, beneficial effect, U.S. veterans have decided to take matters into their own hands and are helping one another to explore DIY approaches to using psychedelics to find relief from their symptoms. Lena Ramsay, who lives in rural Maine, is one such veteran. During her tour in Afghanistan, she suffered a broken vertebra, shattered an ankle and suffered a TBI (traumatic brain injury). VA doctors gave her antidepressants, sleep medication, sedatives and pain medication to help with the different health challenges she…

TuesdayFeb 18, 2025 10:00 am

New Study Shows Ibogaine Can Be Made Without Using Plant Matter

In a study that was featured in Nature Chemistry, researchers at UC Davis have shown that it is possible to manufacture the psychedelic ibogaine without having to harvest tons of the plant in which this substance occurs naturally. Scientists have long had an interest in studying how ibogaine can be leveraged in mental health care. However, the need to harvest enormous amounts of the plant in Africa known to have this substance has presented the research community with a huge challenge. The recent success by the UC Davis team presents a welcome solution to this hurdle. The team led by…

WednesdayFeb 12, 2025 10:00 am

Reports Reveal New York Magazine, Prohibitionists Collaborated to Create Series Against MDMA Therapy

As the psychedelics industry is still reeling from the FDA’s rejection of an application by Lykos Therapeutics seeking approval of MDMA-assisted therapy as a treatment for PTSD, it has emerged that there were concerted efforts to conduct a smear campaign against the possibility of MDMA being approved as a medicine. In a story carried by The New York Post last week, it was revealed that Psymposia, a group that is opposed to the legalization of psychedelics, conducted a protracted campaign to defeat efforts aimed at having MDMA legalized as a therapy for post-traumatic stress disorder. The NYT story highlighted how…

MondayFeb 10, 2025 10:00 am

Cleveland Clinic Researchers to Test Novel Psychedelic Targeting Postpartum Depression

A team of researchers at Cleveland Clinic plans to conduct a clinical trial to test a proprietary psychedelic aimed at treating postpartum depression. This serious condition affects approximately 1 in 7 women after giving birth. The Phase 2 trial centers on RE104, a formulation that is similar to psilocybin. It is designed to be administered subcutaneously via an injection and the patient requires just one dose of this treatment. It is hoped that this treatment will address the clinical needs of new mothers afflicted by PPD and experience symptoms like sleep disturbances, chronically low mood, feelings of guilt or inadequacy,…

WednesdayFeb 05, 2025 10:00 am

Positive Clinical Trial Data Causes Psychedelic Biopharma Company’s Shares to Nearly Double

A small Ireland-based firm, GH Research, has announced positive results from a small trial it conducted to treat treatment-resistant depression. The results from this trial revealed that their inhalable version of mebufotenin was effective and fast in delivering clinically significant improvements in the patients selected for the study. Mebufotenin is molecularly similar to psilocybin and occurs in some psychedelic mushrooms. The shares of the company jumped nearly 100% upon the release of this news. The results of the trial were released on Monday, Jan. 3 and the trial involved 81 participants. The subjects all suffered from treatment-resistant depression, and evaluations…

MondayFeb 03, 2025 10:00 am

Study Finds That Psilocybin Promotes Lasting Belief Changes by Changing Neural Entropy

A new study whose findings were published in the Scientific Reports journal has revealed that psilocybin weakens the negative beliefs that an individual has and promotes well-being by ramping up neural entropy. These findings open additional possibilities for ways in which psychedelic therapy can be used in mental health care. The researchers started by tweaking the REBUS model, which says that psychedelics exert a temporal relaxation of the hierarchical organization in the brain. During this window, flexible thinking can take place. The research team made an extension to this REBUS model by introducing the REBAS model that posits that psilocybin…

WednesdayJan 29, 2025 10:00 am

Estonian Psychiatrists Advocate for the Use of Psychedelics in Treating Mental Health Conditions

Civic activists and psychiatrists in Estonia are calling for the use of psychedelics to treat various mental health conditions. An EMA (Estonian Medicines Agency) representative asserted that psychedelic research is legal in the country and caution needs to be exercised while assessing their adverse effects and therapeutic potential. Psychedelics have a long history both in their use and in scientific research. For example, many people recall the hippies of the 1960s who used LSD and also have heard about enthusiasts of electronic music that use MDMA. These uses of psychedelics invoke associations with narcotics, but that shouldn’t detract from the…

MondayJan 27, 2025 10:00 am

Massachusetts Legislators File 12 Bills Related to Psychedelics for Consideration

Last week, legislators in the state of Massachusetts filed twelve measures related to psychedelics before the filing deadline lapsed. This comes after Question 4, which would’ve decriminalized the use and possession of DMT, ibogaine, psilocybin, psilocin and mescaline and legalized therapeutic access to psychedelics for individuals aged 21 and above, was defeated at the ballot despite support from the general public. Let’s look at some of these latest measures below. Senator Cindy Friedman filed SD 1624, an act that would authorize a pilot for the use of psychedelics in licensed facilities. Under the measure, the Department of Public Health would…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Psychedelic Stocks